# FOCUS ASSET MANAGEMENT

> FOCUS ASSET MANAGEMENT is a VC fund in Yeoksamdong backing Health Care and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Yeoksamdong, South Korea
- Total investments: 4
- Last investment: Apr 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.focusam.co.kr

FOCUS ASSET MANAGEMENT is a VC fund in Yeoksamdong focused on Health Care and Biotechnology. FOCUS ASSET MANAGEMENT provides recruiting and investment advisory services.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Medical | 1 | 25% |
| Genetics | 1 | 25% |
| Software | 1 | 25% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 25% |
| Funding Round | 1 | 25% |
| Post-IPO Equity | 1 | 25% |
| Convertible Note | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NEUROPHET | Neurophet is a medical technology enterprise that focuses on neuro-engineering and brain health. The company develops software programs that utilize artificial intelligence for the analysis of medical brain images. The firm creates simulation tools specifically for medical researchers and doctors who perform non-invasive electrical brainstimulation procedures. These applications allow medical professionals to generate three-dimensional models of individual human brains directly from magnetic resonance imaging data. | $10.8M | Post-IPO Equity | Apr 10, 2026 | http://www.neurophet.com |
| AbClon | AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. | $15.4M | Convertible Note | Sep 29, 2022 | http://abclon.com/ |
| Bertis | Bertis is the AI-Driven proteomics for the Next Era of Precision Medicine. Bertis platform utilises molecular diagnostics to identify cancer-related biomarkers, enabling medical practitioners to detect diseases. | $11.9M |  | Dec 28, 2020 | http://bertis.com |
| Bertis | Bertis is the AI-Driven proteomics for the Next Era of Precision Medicine. Bertis platform utilises molecular diagnostics to identify cancer-related biomarkers, enabling medical practitioners to detect diseases. | $14.6M | Series C | Dec 28, 2020 | http://bertis.com |

4 of 4 investments shown.

## Co-investors
- [BNH Investment](https://shizune.co/investors/profile/bnh-investment) — VC Fund, 2 deals together
- Dreamstone Partners — VC Fund, 2 deals together
- [Kclavis](https://shizune.co/investors/profile/kclavis) — VC Fund, 2 deals together
- Meritz Fire & Marine Insurance — VC Fund, 2 deals together
- [NH Investment & Securities](https://shizune.co/investors/profile/nh-investment-securities) — VC Fund, 2 deals together
- [Premier Partners](https://shizune.co/investors/profile/premier-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does FOCUS ASSET MANAGEMENT invest in?

FOCUS ASSET MANAGEMENT invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did FOCUS ASSET MANAGEMENT last invest?

The most recent investment recorded for FOCUS ASSET MANAGEMENT closed in Apr 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co